• vs. potential COVID-19 treatments
• vs. control
• vs. placebo
• vs. uncontrolled study
• vs. vaccines
• vs. Non replicating viral vector
• vs. Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)

  patient subgroup... adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer beta variant (B.1.351 / 501Y.V2, South Africa) children delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers immunodepression kidney transplant recipients obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC positive for SARS-Cov-2 at baseline solid cancer solid organ transplant recipients subjects at risk     Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

select an endpoint to display result.... display studies ---- color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only observational study